Milan, Italy — 27 January 2026 — IAMA Therapeutics has been awarded the Premio ScaleUp at the Carica delle 101 Awards 2026, in recognition of the […]

GENOA, Italy, April 16, 2025 — IAMA Therapeutics, a biotechnology company focused on the neuroscience drug discovery and start-up of Istituto Italiano di Tecnologia (Italian Institute […]

San Diego, CA – March 26, 2025 — On Wednesday, March 26 at 2:35 p.m. PDT, Marco Borgogno, PhD, Head of Discovery at IAMA Therapeutics, will present the first public data on our investigational […]

Milan, Italy — 26 November 2024 — Innovation made in Italy takes center stage once again. IAMA Therapeutics has been honored with the Premio Innovazione SEmi, the annual award bestowed by […]

Milan, Italy — 21–24 September 2024 — IAMA Therapeutics is headed to the 37th European College of Neuropsychopharmacology (ECNP) Congress, Europe’s premier forum for brain research and clinical innovation. […]

Vienna, Austria — 26 June 2024 — IAMA Therapeutics is in the spotlight this week at the FENS Forum 2024 (#FENS2024), Europe’s largest neuroscience meeting, taking place 25–29 June at the Messe Wien […]

GENOA, Italy, April 11, 2024 — IAMA Therapeutics today announced the appointment of Federico Bolognani, MD, PhD, as Chief Medical Officer (CMO). Bringing extensive expertise in […]

GENOA, Italy, February 19, 2024 — IAMA Therapeutics has successfully dosed the first two cohorts of subjects and has started dosing the third one in the […]

GENOA, Italy, January 23, 2024 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]